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Myostatin, a TGF-𝛽 family member, is associated with inhibition of muscle growth and differentiation and might interact with
the IGF-1 signaling pathway. Since IGF-1 is secreted at a bioactive level by adipose tissue-derived mesenchymal stem cells (ASCs),
these cells (ASCs) provide a therapeutic option for Duchenne Muscular Dystrophy (DMD). But the protective effect of stem cell
secreted IGF-1 on myoblast under high level of myostatin remains unclear. In the present study murine myoblasts were exposed to
myostatin under presence of ASCs conditioned medium and investigated for proliferation and apoptosis. The protective effect of
IGF-1 was further examined by using IGF-1 neutralizing and receptor antibodies as well as gene silencing RNAi technology. MyoD
expression was detected to identify impact of IGF-1 onmyoblasts differentiation when exposed tomyostatin. IGF-1 was accountable
for 43.6% of the antiapoptotic impact and 48.8% for the proliferative effect of ASCs conditioned medium. Furthermore, IGF-1
restored mRNA and protein MyoD expression of myoblasts under risk. Beside fusion and transdifferentiation the beneficial effect
of ASCs is mediated by paracrine secreted cytokines, particularly IGF-1. The present study underlines the potential of ASCs as a
therapeutic option for Duchenne muscular dystrophy and other dystrophic muscle diseases.
1. Introduction
Duchenne muscular dystrophy (DMD) is caused by muta-
tions in the dystrophin gene and patients suffer fromdecrease
of muscle tissue [1, 2]. By age of 12 most patients are
wheelchair-bound and die early between the age of 20–
30 due to respiratory failure. The progressive fiber dam-
age and membrane leakage are caused by the destabilized
dystrophin-associated protein complex (DAPC) due to the
missing dystrophin protein. In fact, a single exposure to high-
force eccentric contractions without prior adaptation induce
a loss of DAPC components and apoptosis in normal muscle
tissue [3, 4]. Normal muscles tissue, repeatedly subjected to
mechanical overload, respondwith growth and adaptingwith
a greater resistance to membrane wounding [5]. It has been
demonstrated that endurance training upregulates IGF-1 and
IGF2 mRNA as well as IGF regulatory proteins (IGFBP2,
IGFBP4, IGFBP7, and PRSS11). This is of particular impor-
tance, since IGF signaling pathway interacts with TFG-b
signaling, influencingmuscle cell differentiation and prolifer-
ation in a complex manner [6]. TGF-𝛽 protein concentration
has been shown to be elevated in dystrophic muscle whereas
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Figure 1: The pLVX-Puro-HS-GR vector was constructed by cloning HS-GR cassette into CMV driven lentiviral backbone (Clontech)
betweenXhoI andXbaI restriction sites. H2B: histone protein sequence; 2A: self-cleavage peptide; SS: endoplasmatic reticulum signal peptide;
GPI: C terminal GPI anchor sequence; pA: bovine growth hormone polyadenylation signal.
this protein did not appear in the exercise training analysis
for normal muscle tissue [7, 8]. Especially, myostatin, a new
member of the TGF-𝛽 superfamily, has been reported to
be a negative regulator of skeletal muscle growth [9]. This
would suggest a role of TGF-𝛽 in the degeneration of skeletal
muscles in DMD (e.g., disruption of IGF-related signaling).
Indeed, application of IGF-1 attenuates the deterioration of
skeletal muscles mass in a murine Duchenne (mdx) model
[4, 10].
Previous studies demonstrated beneficial effects of IGF-
1 produced by mesenchymal stem cells, particularly by adi-
pose tissue-derived stem cells (ASCs) which can be easily
harvested and expanded in vitro [11]. Thus, this study was
performed to investigate whether paracrine factors secreted
by ASCs are able to stimulate proliferation of myoblasts
and ameliorate myostatin effects on myoblasts. Moreover, we
wanted to elucidate the role of IGF-1 and its protective role
for myoblasts when exposed to an elevated myostatin level.
2. Materials and Methods
2.1. Cell Culture. Adipose tissue was harvested from the
inguinal fat pads of five male BALB/c mice (Jackson Lab-
oratory) at the age of 8–12 weeks and pooled for further
processing.The tissuewaswashed twice with prewarmed PBS
prior to mincing. Two units of LiberaseMNP-S (Roche) were
mixed in 1mLprewarmedDulbecco’smodified eaglemedium
(DMEM) (Invitrogen) per gram fat and incubated at 37∘C
225 rpm shaking for 30 minutes followed by mixing with a
pipette to release cells. Afterwards, mixture was centrifuged
at 500 g for 10min and cell pellet was washed three times with
PBS.The resulting cell pelletwas resuspended andpropagated
in complete ASCs culture medium (DMEM) supplemented
with 20% fetal bovine serum (FBS, PAN-Biotech), 100U/mL
Penicillin (Sigma), and 100 𝜇g/mL streptomycin (Sigma) and
incubated at 37∘C in a humidified atmosphere containing 5%
CO
2
. C2C12 cells (ATCC) were cultured in growth medium
consisting of DMEM, 10% FBS, 100U/mL Penicillin, and
100 𝜇g/mL streptomycin. Myoblasts were subcultured before
reaching 80% confluency and used for all experiments before
passage 7.
For lentiviral production, human embryonic kidney 293T
cells (HEK293T, ATCC) were grown in DMEM containing
10% FBS and used in passages below 20.
2.2. Real-Time Fusion Assay. A plasmid containing H2B-
EGFP-2A-mCherry-GPI (HS-GR) was generously provided
by Dr. Richard Beheringer and Chuan-Wei Jang (MDAnder-
son Cancer Center). A lentiviral construct was generated by
subcloning the HS-GR cassette into the pLVX-Puro vector
(Clontech) between Xhol and Xbal by restriction digest and
ligation (Figure 1). The integrity of cloned HS-GR cassette
was confirmed by DNA sequencing and resulting vector was
named pLVX-Puro-HS-GR.
ASCs were stable transfected by lentiviral infection as
described below. DAPI dye was added to myoblast cell
culture at a final concentration of 50𝜇g/mL in 10% FBS
supplemented DMEM and incubated for 30 minutes. DAPI
labeled myoblasts and pLVX-Puro-HS-GR expressing ASCs
cultured in 20% FBS supplemented DMEM were rinsed six
times with PBS and trypsinized for coculture fusion assay.
8 × 104 DAPI labeled C2C12 and 2 × 104 pLVX-Puro-HS-
GR labeled ASCs were mixed and placed in a 6-well plate and
incubated until cell culture reached 100% confluency using
myoblast specific medium (DMEM, 10% FBS, 100U/mL
Penicillin, and 100 𝜇g/mL streptomycin). Afterwards, media
was switch to fusion media (DMEM supplemented with
2% horse serum) and replaced every second day. Control
group of ASC cell culture was propagated in fusion media to
monitor spontaneous fusion of cells.
2.3. Lentiviral Particle Production and Transduction of ASCs.
Commercial available short hairpin RNA (shRNA) con-
structs were obtained as bacterial glycerol stocks (Sigma)
and used to silence murine IGF-I. Plasmid DNA of shRNA
and pLVX-Puro-HS-GR vector was purified using a plasmid
extraction kit (Plasmid Maxi Kit, Qiagen). Lentiviral vector
particles were produced by three plasmid cotransfection
onto HEK 293T with 40 𝜇g of shRNA or pLVX-Puro-HS-
GR vector DNA, 30 𝜇g pCMV-ΔR8.91 (The Broad Institute,
MA, USA), and 10 𝜇g pMD2.G (Addgene, clone 12259) using
a calcium-phosphate transfection kit (Invitrogen). Lentivi-
ral vector concentration was determined by p24 ELISA
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Table 1: Primer sets for SYBR Green assay.
Primer Tm Sequence
Actin 55∘C Sense CAGGTCCAGACGCAGGATGGC
Antisense CTACAATGAGCTGCGTGTGGC
MyoD 57∘C Sense GGTCTGGGTTCCCTGTTCTGTGT
Antisense CCCCGGCGGCAGAATGGCTACG
GAPDH 67∘C Sense AGCCACATCGCTCAGACACC
Antisense GTACTCAGCCGCCAGCATCG
IGF-1 60∘C Sense GCTGGTGGAAGCTCTTCAGTTC
Antisense AGCTGACTTGGCAGGCTTGAG
(Cell Biolabs). ASCs were transduced in passage 2 with
2.56 × 105 TU/mL virus and polybrene (8 𝜇g/mL) (Chemi-
con). After 8 hours, the medium was replaced by fresh
DMEM. Twenty-four hours later, antibiotic selection (1.3𝜇M
puromycin) was initiated for 10 days following additional
4-day recovery. ASCs transduced with nontarget shRNA
(Sigma) served as negative controls. Stable silencing of IGF-I
in ASCs was determined by SYBR Green assay (Biorad) and
ELISA (RnD System).
2.4. Apoptosis and Proliferation Assay. 1 × 103 C2C12 cells
were seeded in quintuplicates into a 96-well plate and treated
with myostatin after 24 hours resting period followed by
further 24 hours incubation. Apoptosis of myoblasts after
various myostatin concentrations (RnD Systems) was inves-
tigated by Cell Death Detection Kit (Roche) according to
instruction manual.
In order to quantify proliferation of murine C2C12 under
myostatin treatment cells were seeded at concentration of
1 × 103 in each well of the 96-well plate and proliferation was
detected by a BrdU kit (Roche) according to the manufac-
turer’s instruction. In detail, cells were seeded in quintuplicate
and allowed to attach for 24 hours followed by myostatin
exposure under specific treatment conditions for another
24 hours. Myostatin was added to conditioned medium at
indicated final concentration prior to myoblasts incubation.
IGF-1 receptors ofmyoblasts were blocked by adding receptor
antibodies (Abcam) 30 minutes prior to myostatin incuba-
tion. IGF-1 receptor and IGF-1 neutralizing antibody (RnD
System) were simultaneously added to myoblasts in addition
to myostatin and incubated for 24 hours.
2.5. Conditioned Medium. Conditioned medium of ASCs
was used to investigate the effect of ASCs paracrine factors.
Serum free DMEM medium containing antibiotics (peni-
cillin, streptomycin) was added to 90% confluent ASCs and
collected after 48 h.The conditionedmediumwas centrifuged
at 500 g for 5 minutes and subsequently filtered by a 0.22
micron filter (Millipore). Fresh prepared CM of wild type
ASCs, IGF-1 shRNA, and nontarget shRNA transfected ASCs
were used for further experiments.
2.6. Western Blot. C2C12 cells were seeded in order to obtain
40% confluent cultures prior to adding serum-reduced (2.5%
FBS) medium or conditioned medium (CM) containing
0.75 𝜇g/mL myostatin. Total protein content of cell culture
was extracted after 72 hours of myostatin incubation when
culture reached 70% confluency. First, C2C12 cells were
rinsed twice with PBS and trypsinized followed by centrifu-
gation at 500 g for 5 minutes.The cell pellet was washed twice
with ice cold PBS subsequently lysed with fresh prepared
RIPA-B-buffer and incubated on ice for 15 minutes followed
by centrifugation at 13.000 g for 20 minutes at 4∘C. Protein
concentration was measured by using Bradford method (Dc
Protein Assay kit, BioRad) and samples were prepared with
Laemmli buffer (BioRad) for SDS-PAGE. Gels were loaded
with 90𝜇g total protein and run for 50minutes at 100V.After-
wards, the gel was blotted on a nitrocellulose membrane for
one hour at 100V. The nitrocellulose membrane was blocked
in fresh prepared TBS-T/5% milk at room temperature for
one hour. MyoD primary antibody (Santa Cruz; sc-71629)
was used at a dilution of 1 : 200 and 𝛽-Actin primary antibody
(cell signaling, number 4967) at a dilution of 1 : 1000 and
incubated at 4∘Covernight.Thenitrocellulosemembranewas
washed four times for five minutes with TBS-T and subjected
to appropriate secondary antibody Anti-mouse IgG (DyLight
800 or 680, Cell Signaling) for one hour at room temperature.
The Infrared Imaging System Odysee (Licor) was used to
obtain digital reading of Western blot.
2.7. Real-Time PCR. Total RNA was extracted from cell cul-
ture using RNAqueous-Micro-Kit according tomanufactures
protocol and stored at −80∘C until further investigations.
Using iScript cDNA Synthesis Kit (BioRad) RNA was reverse
transcribed into cDNA according to manufacturer’s instruc-
tions. To determine MyoD mRNA expression quantitative
analyses were performed using Eco qPCR system (illumina)
with DyNAmo ColorFlash SYBR Green assay (Biozyme)
and appropriate primer set (8 nM final concentration) 𝛽-
Actin and GAPDH primer set served as a housekeeping gene
reference (Table 1).
2.8. Statistical Analysis. Results are shown as mean ± SD
with at least 3 replicates. In addition, all experiments were
performed 3 times. For pair wise comparison, a Student’s t-
test was carried out, and for group wise comparison, one-way
ANOVA with Scheffe post hoc correction was carried out by
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Figure 2: Flowcytometry analyses of ASCs for hematopoietic and endothelial cell markers as well as for mesenchymal cells surface proteins.
(a) (b) (c)
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Figure 3: Fusion of DAPI labeled murine myoblasts (blue nucleus) and murine ASCs carrying the pLVX-Puro-HS-GR vector (red cell
membrane, green nucleus) monitored by immunofluorescence ((a)–(c)) and phase contrast microscopy overlay ((d)–(f)). The red cell
membrane surrounding blue and green nuclei indicates a fusion between myoblasts and ASCs (white arrow indicating myotubes generated
by fusion).
using SPSS statistical software package (SPSS Inc., IL, USA).
Values at 𝑃 < 0.05 were considered as statistically significant.
3. Results
3.1. Characterization of ASCs. Flowcytometry analyses were
performed on ASCs for hematopoietic and endothelial cell
markers as well as for mesenchymal cells surface proteins.
ASCs were positive for CD44 (95.44% ± 2.66), CD90 (97.17%
± 4.05), and CD105 (98.54% ± 1.89) and negative for CD11b
(0.25% ± 0.14), CD14 (0.13% ± 0.09), CD34 (0.92% ± 1.51),
and CD45 (0.26% ± 0.30), which preclude contamination by
hematopoietic cells. HLA-DR, a class II antigen of HLA, was
also negative (0.94% ± 0.68) for ASCs (Figure 2).
3.2. Fusion of Murine ASCs and Murine Duchenne Myoblasts.
DAPI labeled murine Duchenne myoblasts and pLVX-Puro-
HS-GR labeledmurine ASCs were cocultured andmonitored
for myotube formation in order to evaluate whether murine
ASCs contribute to myotubes by fusion. After 3–5 days DAPI
and GFP labeled nuclei were found to be surrounded by a red
cell membrane clearly indicating a fusion of both cell types
(Figure 3).
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Figure 4: (a) Proliferation of murine myoblasts is shown as percentage after exposure to different myostatin concentrations for 24 h.
Increasing concentrations of myostatin were associated with decreased proliferation rate of murine myoblasts. Myoblasts cultured with
1.0𝜇g/mL myostatin for 24 h showed lowest proliferation (33.2%) in comparison to 0.75 𝜇g/mL (52.0%), 0.5 𝜇g/mL (53.6%), and 0.1 𝜇g/mL
(90.87%) ( ∗𝑃 < 0.001, in comparison to control group). (b) Apoptotic effect of myostatin on murine myoblasts is shown as percentage of
apoptotic cells.Murinemyoblasts exposed to 1.0 𝜇g/mLmyostatin for 24 h showed highest apoptotic rate of 92.4% in comparison to 0.5 𝜇g/mL
(69.3%), 0.1 𝜇g/mL (48.6%), and 0.01 𝜇g/mL (13.9%) ( ∗∗𝑃 < 0.001, in comparison to control group).
3.3. Myostatin Induces Apoptosis onMyoblast Cell and Inhibits
Myoblast Proliferation. To investigate the apoptotic effect
of myostatin on myoblasts, increasing concentrations (0.01–
1.0 𝜇g/mL) of murine myostatin were added to murine
myoblasts and incubated for 24 h. Addition of 0.01 𝜇g/mL
myostatin did not show a significant increase in apopto-
sis of murine myoblast cells. Murine myoblasts exposed
to 1.0 𝜇g/mL myostatin for 24 h showed highest apoptotic
rate of 92.4% in comparison to 0.5 𝜇g/mL (69.3%) and
0.1 𝜇g/mL (48.6%) (𝑃 < 0.001, in comparison to control
group, Figure 4(a)). Proliferation of myoblasts was analyzed
after 24 h myostatin exposure by performing a colorimetric
BrdU-based ELISA. Addition of various myostatin concen-
trations resulted in a significant decrease (𝑃 < 0.001)
of myoblasts proliferation whereas myoblasts cultured with
1.0 𝜇g/mL myostatin showed lowest proliferation (33.2%) in
comparison to 0.75 𝜇g/mL (52.0%), 0.5 𝜇g/mL (53.6%), and
0.1 𝜇g/mL (90.87%) (<0.001, in comparison to control group,
Figure 4(b)).
The concentration of 0.75𝜇g/mL myostatin was selected
for subsequent experiments due to significant effects on
myoblasts apoptosis and proliferation.
3.4. IGF-1 Is Accountable for Protective Effect of ASCs Con-
ditioned Medium. Paracrine factors of ASCs were investi-
gated for their effect on myoblasts’ proliferation exposed to
myostatin.The proliferation decreased bymyostatin to 54.8%
(±3.2%) was significantly abrogated by stem cell conditioned
medium and increased to 76.4% (±2.7%) (Figure 5(a)). Neu-
tralization antibodies against IGF-1 and its corresponding
receptor were simultaneously added to conditioned medium
in order to elucidate the protective role of IGF-1 secreted
by ASCs. Proliferation of myoblasts decreased from 76.4%
(±2.7%) to 65.8% (±2.9%) after blocking IGF-1 ligand-
receptor interaction. Thus, IGF-1 secreted by ASCs accounts
for ∼51% of the protective effect on myoblasts proliferation
when exposed to myostatin.
Furthermore, CM of ASCs reduced apoptosis rate of
myostatin treated myoblasts from 75.5% (±8.7%) to 22.8%
(±4.2%). But, after blocking the effect of IGF-1 in conditioned
medium of ASCs the apoptosis rate significantly increased to
66.3% (±7.3%) (𝑃 < 0.001, Figure 5(b)). Thus, 82.5% of the
antiapoptotic effect of the CM is due to IGF-1 secreted by
ASCs.
3.5. IGF-1 Restores MyoD Expression in Myoblasts. MyoD
expression at mRNA and protein level was investigated
to evaluate the influence of IGF-1 on murine myoblast
transdifferentiation. First, the expression of IGF-1 was sup-
pressed by a lentiviral shRNA vector construct in ASCs
and efficiency was assessed by quantitative real-time PCR
(97%) and ELISA (85%). ASCs showed a high expression
of IGF-1 protein (328.33 ± 22.7 pg/𝜇g DNA) which was not
affected by nontarget shRNA transfection. MyoD mRNA
expression in myoblasts treated with 0.75𝜇g/mL myostatin
for 72 h decreased to 22.8% (±4.6%) in comparison to
untreatedmyoblasts. Conditionedmediumofwild typeASCs
could partially abolish the negative effect of myostatin since
MyoD mRNA significantly increased to 51.2% (±5.9%). This
positive effect was accountable for IGF-1 by 87.3% since IGF-1
depleted CM decreasedMyoDmRNA level to 26.4% (±3.4%)
(Figure 6).
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Figure 5: (a) Effect of conditioned medium onmyoblasts’ proliferation is shown as percentage after 48 hmyostatin exposure. Proliferation of
murine myoblast cultured in 0.75 𝜇g/mL myostatin significantly decreased to 54.8% (±3.2%, ∗∗𝑃 < 0.001), whereas conditioned medium of
ASCs significantly increased myoblasts’ proliferation under 0.75𝜇g/mLmyostatin incubation to 76.4% (±2.7%, ∗∗𝑃 < 0.001).This protective
effect was abolished after neutralization of IGF-1 ligand-receptor interaction and proliferation significantly decreased to 65.8% (±2.9%, ∗∗𝑃 <
0.001). (b) Myoblasts exposed to 0.75𝜇g/mL myostatin showed a significant increase in apoptosis rate to 75.5% (±8.7%) but were reduced
to 22.8% (±4.2%) due to paracrine factors of ASCs conditioned medium ( ∗∗𝑃 < 0.001). The protective effect of ASCs conditioned medium
was abolished after blocking IGF-1 and its receptor whereas apoptotic rate increased to 66.3% (±7.3%) ( ∗∗𝑃 < 0.001). Thus, IGF-1 secreted
by ASCs accounts for 82.5% of the antiapoptotic effect of the CM (𝑁 = 3, 𝑛 = 3).
The expression of MyoD protein was examined in
myoblast cells under 0.75 𝜇g/mL myostatin exposure with
and without conditioned medium. Control samples clearly
showed MyoD protein expression whereas protein was no
longer detectable after myostatin treatment. But, addition of
conditioned medium to myoblasts under myostatin treat-
ment demonstrated a weak but distinct detection of MyoD
protein expression (Figure 7).
4. Discussion
The aim of the study was to examine the regenerative poten-
tial of ASCs mediated by the secretion of paracrine factors
particularly IGF-1 for dystrophicmuscle diseases considering
myostatin as a negative regulator of skeletal muscle mass.
Stem cell based therapy provides a promising treatment
option for DMD since fusion between healthy stem cells
and dystrophic myoblasts restored dystrophin expression in
vitro and in vivo [12, 13]. We confirmed previous results
that dystrophic myoblasts fuse with ASCs but clearly provide
the evidence that nuclei from both cell types are apparent
in emerged myotubes. The nucleus and the cell membrane
of one cell line were labeled with two different fluorescent
proteins in the present study andweremonitored in real time.
This represents a method superior to a single fluorescent cell
labeling approach for fusion since currently used dyes (e.g.,
DAPI, Dio, Dil, DiD, quantum dots) provide only transient
staining restricted to specific cell organelles (i.e., nucleus,
cytoplasm, or mitochondria).
Fusion is a feature of myogenic precursor cells occurring
after activation of muscle satellite cells in order to restore
affectedmuscle tissue. But tremendous destruction of muscle
cells reduces the capacity of satellite cells regarding pro-
liferation and self-renewal [14]. Thus, application of stem
cells provides muscle tissue with a cell population presenting
intact self-renewal and proliferation potential. More recently,
it has been shown thatmouse adipose tissue stem cells restore
dystrophin expression in mdx mice [12] but only at the site
of injection [15]. Previous studies and our results provide
evidence that ASCs possess the capacity to contribute to
muscle regeneration by gene expression modification after
fusion. However, the paracrine effects of ASCs have not
been investigated on dystrophic myoblast as previously for
myocardial infarction [11] or hind limb ischemia [16]. The
major finding of this study is that IGF-1 secreted by ASCs
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Figure 6: Relative quantification of MyoD mRNA is shown as
mean ± SD percentage of MyoD mRNA expression in murine
myoblasts after 72 h myostatin treatment. Myostatin exposure sig-
nificantly reduced MyoD mRNA to 22.8% (±4.6%, ∗∗𝑃 < 0.001) in
comparison to untreatedmyoblasts. Due to the effect of conditioned
medium fromwild type ASCsMyoD, mRNA significantly increased
to 51.2% (±5.9%, ∗∗𝑃 < 0.001) when compared to myostatin
treatment. But this effect was accountable for IGF-1 by 87.3% since
IGF-1 depleted CM decreased MyoD mRNA level to 26.4% (±3.4%,
n.s. compared to myostatin treatment) (𝑁 = 3, 𝑛 = 3).
increase MyoD expression in myostatin treated myoblasts.
Furthermore, the paracrine factors of ASCs, particularly
IGF-1, provide protective effects on murine myoblasts under
myostatin treatment.
IGF-1 plays an essential role in muscle development,
muscle cell proliferation, and muscle growth as already
reported for insulin [17, 18] due to its structural resemblance.
However, the anabolic function of IGF-1 is based on the
interaction between binding proteins and IGF-1 receptor in
an autocrinal and hormonal manner [19].
In contrast, TGF-𝛽 acts as an antagonist of IGF-1 by using
the same signaling cascade (PI3K/Akt/GSK-3𝛽 pathway)
[20]. This is of interest, since previous studies indicated an
elevated TGF-𝛽 protein level in dystrophic muscles [7, 8].
Noteworthy, myostatin belongs to the TGF-𝛽 family and
is known as an inhibitor of muscle growth and myoblasts’
proliferation [21, 22]. In line, in vitro studies provided
evidence that application of recombinant myostatin [23] or
myostatin transfected myoblasts [24] was associated with
decreased proliferation ofmuscle cells. Recently, it was shown
that dystrophic muscle disease symptoms decreased in mdx
mice when treated with myostatin antibodies [9].
These findings indicate that myostatin is involved in
degeneration of skeletal muscles in DMD and that IGF-1
might be able to improve the inhibitory effect of myostatin on
muscle growth. We for the first time could demonstrate that
IGF-1 secreted by ASCs improves proliferation and viability
of myostatin treated myoblasts. In line, hypertrophic effects
1 2 3 4
Conditioned
medium
Myostatin
−
− −
+ +
+
(0.75𝜇g/mL)
Figure 7: Representative Western blot analysis of MyoD protein
expression. Nontreated cells clearly showed an expression of MyoD
protein (lane 2) whereas no MyoD protein was detected after
incubation with myostatin (lane 3). After incubation with CM of
ASCs a weak but significant expression of MyoD was detectable by
Western blot analyses (lane 4). A total protein amount of 90𝜇g was
loaded on each lane. Green arrow indicates the band of MyoD and
red arrow indicates 𝛽-Actin as loading control (𝑁 = 3).
on skeletal muscles were demonstrated in vivo for IGF-1
overexpressing mouse [25]. Moreover, muscle hypertrophy
due to exercise is mediated by upregulation of IGF-1 mRNA
[26]. But excessive physical muscle activity is critical for
DMD patients and results in muscle fiber damage.
Gregorevic et al. [27] showed an improvement of muscle
fatigue in EDL (extensor digitorum longus) and soleus mus-
cles in IGF-1 treatedmdxmice. IGF-1 is able to activatemuscle
growth and hypertrophy and seems to ameliorate the loss of
musclemass inDMD.However, growth factors have a limited
half-life and are small in size, which restricts their retention
within a tissue for prolonged periods. Moreover, systemic
administration of growth factors has shown amodest success
or unpleasant side effects in a number of in vivo studies
even when using gene transfer [23–26]. For this reason, cell
based therapy is advantageous since mesenchymal stem cells
produce antiapoptotic factors at a bioactive level [7].
Activation of muscle differentiation requires myogenic
regulatory factors (MRFs) consisting of four transcription
factors includingMyoD,myogenin,Myf5, andMRF4 [28, 29].
Of importance, quiescent satellite cells express no detectable
levels of MRFs and first express MyoD or Myf-5 after
activation. Regeneration inMyoD−/−muscle is characterized
by almost complete abolished proliferation of myogenic cells
[30]. In line, Langley et al. [31] provided evidence that
MyoD expression is significantly decreased in myoblasts by
myostatin treatment.Moreover,MyoD can be downregulated
by myostatin treatment even after initial induction due to
myogenic differentiation. In addition, the study revealed
that myostatin treatment increased Smad3 level that coim-
munoprecipitated with MyoD suggesting Smad3 binding to
MyoD thereby inhibiting muscle differentiation. IGF-1 has
8 BioMed Research International
been reported to block Smad3 activation via a phosphatidyli-
nositol 3-kinase (PI3K)/Akt dependent pathway and thereby
inhibiting TGF-𝛽 signaling [32]. Moreover, Trendelenburg
et al. reported that myostatin inhibits the activation of Akt
signaling and IGF-1 treatment can counteract myostatin’s
antidifferentiation effects [33].These previous results support
our findings that IGF-1 secreted by ASCs can restore the
negative effect of myostatin on MyoD expression.
5. Conclusion
The present study indicates that IGF-1 secreted by ASCs
improves the catabolic effect of myostatin on myoblasts. In
addition, our results support that ASCs might represent a
valuable cell source for local application in DMD treatment
due to their high secretion of bioactive IGF-1. These results
show the important paracrine action of adipose tissue derived
stem cells in therapy for muscular dystrophies and muscle
wasting diseases.
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